Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

MONROVIA, Calif., HONG KONG and BOSTON, Nov. 21 (Korea Bizwire) — Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas BioPharma (“Zenas”), a global biopharmaceutical company based in the USA and China committed to the development and delivery of immune-based [...]